184475-35-2 Gefitinib AKSci J10250
 
 
Loading Please Wait...
  J10250    
Gefitinib
, >98% (HPLC)
 
Iressa
Irressat
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine




IDENTITY
CAS Number:184475-35-2
MDL Number:MFCD04307832
MF:C22H24ClFN4O3
MW:446.9
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:188-198°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO: 89mg/mL; H2O: <1mg/mL; EtOH: 4mg/mL
Application(s):Orally active, selective EGFR inhibitor
Form:Free Base

REVIEW

 Gefitinib is the first selective inhibitor of epidermal growth factor receptor''s (EGFR) tyrosine kinase domain. The target protein (EGFR) is a family of receptors which includes Her1(erb-B1), Her2(erb-B2), and Her 3(erb-B3). EGFR is overexpressed in the cells of certain types of human carcinomas. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways. These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.

REFERENCES
[1]Pao W, Miller V, Zakowski M, et al. (September 2004). EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America 101 (36): 13306-11. doi:10.1073/pnas.0405220101. PMC 516528. PMID 15329413.
[2] Sordella R, Bell DW, Haber DA, Settleman J (August 2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (5687): 1163-7. doi:10.1126/science.1101637. PMID 15284455.
[3] Takimoto CH, Calvo E. Principles of Oncologic Pharmacotherapy in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
[4] Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009; 361. 10.1056/NEJMoa0810699.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of April 24, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem